Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

June 10, 2008 11:00 ET

Ambrilia Unveils its Complete Antivirals Portfolio and Highlights Progress Made in the Strategic Plan Execution


MONTREAL, QUEBEC--(Marketwire - June 10, 2008) -

Editors Note: Two photos for this release will be available via Marketwire on the picture wire of The Canadian Press.

Philippe Calais, President and CEO of Ambrilia Biopharma Inc. (TSX:AMB), today unveiled during its Annual General Meeting the Company's complete antivirals portfolio comprising of small molecules and peptides targeting HIV/AIDS, Hepatitis C and Influenza A, as well as highlighted the latest progress made in the strategic plan execution. "Important strides were made recently and now Ambrilia has in hand a safe and effective Phase III product, as well as a final Goserelin formulation, each targeting $1 billion-plus markets," said Philippe Calais. "We are advancing well in the process of monetizing these major non-virology assets through third party agreements. This represents a core objective of the strategic plan execution which should enable the Company to strengthen its financial position as well as focus on its longer-term value drivers, its unique antivirals." For more information, please visit the Company's web site:


Contact Information